JP5663595B2 - ドライアイ症候群の治療のための医薬組成物 - Google Patents

ドライアイ症候群の治療のための医薬組成物 Download PDF

Info

Publication number
JP5663595B2
JP5663595B2 JP2012542577A JP2012542577A JP5663595B2 JP 5663595 B2 JP5663595 B2 JP 5663595B2 JP 2012542577 A JP2012542577 A JP 2012542577A JP 2012542577 A JP2012542577 A JP 2012542577A JP 5663595 B2 JP5663595 B2 JP 5663595B2
Authority
JP
Japan
Prior art keywords
composition
eye
ethanol
treatment
dry
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012542577A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013513586A (ja
JP2013513586A5 (enExample
Inventor
タイジンガー バスチャン
タイジンガー バスチャン
タイジンガー ゾンニャ
タイジンガー ゾンニャ
グンター バーンハルド
グンター バーンハルド
Original Assignee
ノバリック ゲーエムベーハー
ノバリック ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41731659&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5663595(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバリック ゲーエムベーハー, ノバリック ゲーエムベーハー filed Critical ノバリック ゲーエムベーハー
Publication of JP2013513586A publication Critical patent/JP2013513586A/ja
Publication of JP2013513586A5 publication Critical patent/JP2013513586A5/ja
Application granted granted Critical
Publication of JP5663595B2 publication Critical patent/JP5663595B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2012542577A 2009-12-14 2010-12-13 ドライアイ症候群の治療のための医薬組成物 Active JP5663595B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09015423.8 2009-12-14
EP09015423A EP2335735A1 (en) 2009-12-14 2009-12-14 Pharmaceutical composition for treatment of dry eye syndrome
PCT/EP2010/069495 WO2011073134A1 (en) 2009-12-14 2010-12-13 Pharmaceutical composition for treatment of dry eye syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014203406A Division JP6096731B2 (ja) 2009-12-14 2014-10-01 ドライアイ症候群の治療のための医薬組成物

Publications (3)

Publication Number Publication Date
JP2013513586A JP2013513586A (ja) 2013-04-22
JP2013513586A5 JP2013513586A5 (enExample) 2014-01-09
JP5663595B2 true JP5663595B2 (ja) 2015-02-04

Family

ID=41731659

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2012542577A Active JP5663595B2 (ja) 2009-12-14 2010-12-13 ドライアイ症候群の治療のための医薬組成物
JP2014203406A Active JP6096731B2 (ja) 2009-12-14 2014-10-01 ドライアイ症候群の治療のための医薬組成物
JP2016248533A Active JP6397472B2 (ja) 2009-12-14 2016-12-22 ドライアイ症候群の治療のための医薬組成物
JP2018163569A Pending JP2019006803A (ja) 2009-12-14 2018-08-31 ドライアイ症候群の治療のための医薬組成物
JP2018248700A Active JP6731039B2 (ja) 2009-12-14 2018-12-28 ドライアイ症候群の治療のための医薬組成物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2014203406A Active JP6096731B2 (ja) 2009-12-14 2014-10-01 ドライアイ症候群の治療のための医薬組成物
JP2016248533A Active JP6397472B2 (ja) 2009-12-14 2016-12-22 ドライアイ症候群の治療のための医薬組成物
JP2018163569A Pending JP2019006803A (ja) 2009-12-14 2018-08-31 ドライアイ症候群の治療のための医薬組成物
JP2018248700A Active JP6731039B2 (ja) 2009-12-14 2018-12-28 ドライアイ症候群の治療のための医薬組成物

Country Status (15)

Country Link
US (1) US8614178B2 (enExample)
EP (2) EP2335735A1 (enExample)
JP (5) JP5663595B2 (enExample)
KR (2) KR101722039B1 (enExample)
CN (1) CN102652022B (enExample)
AU (1) AU2010333039B2 (enExample)
BR (3) BR122020020872B1 (enExample)
CA (2) CA2776860C (enExample)
DK (1) DK2512515T3 (enExample)
ES (1) ES2449308T3 (enExample)
IN (1) IN2012DN03128A (enExample)
MX (1) MX2012006720A (enExample)
PL (1) PL2512515T3 (enExample)
PT (1) PT2512515E (enExample)
WO (1) WO2011073134A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2437684B1 (en) 2009-06-03 2022-06-15 ForSight Vision5, Inc. Anterior segment drug delivery
ES2564502T3 (es) 2010-03-17 2016-03-23 Novaliq Gmbh Composición farmacéutica para el tratamiento de la presión intraocular aumentada
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
CN103561724B (zh) 2011-05-25 2016-06-29 诺瓦利克有限责任公司 给药给甲的药物组合物
JP6039145B2 (ja) 2011-05-25 2016-12-07 ノバリック ゲーエムベーハー 半フッ化アルカンを基礎にした局所薬学的組成物
PT2806886T (pt) 2012-01-23 2017-03-24 Novaliq Gmbh Composições de proteínas estabilizadas baseadas em alcanos semifluorados
MX363182B (es) * 2012-09-12 2019-03-13 Novaliq Gmbh Composiciones que comprenden mezclas de alcanos semifluorados.
EP2895144B1 (en) 2012-09-12 2017-01-11 Novaliq GmbH Semifluorinated alkane compositions
PL2708228T3 (pl) 2012-09-12 2018-11-30 Novaliq Gmbh Kompozycje do przemywania oczu
EP2730291A1 (en) * 2012-11-09 2014-05-14 Fluoron Gmbh Internal Tamponade Composition
US10172789B2 (en) 2013-01-24 2019-01-08 Palvella Therapeutics Llc Compositions for transdermal delivery of mTOR inhibitors
JP6304475B2 (ja) * 2013-01-31 2018-04-04 ロート製薬株式会社 点眼剤
TWI623313B (zh) * 2013-03-13 2018-05-11 Santen Pharmaceutical Co Ltd 瞼板腺功能障礙之治療劑
DK3024484T3 (en) 2013-07-23 2018-10-08 Novaliq Gmbh STABILIZED ANTIBODY COMPOSITIONS
US20160243291A1 (en) * 2013-10-15 2016-08-25 Forsight Vision5, Inc. Formulations and Methods for Increasing or Reducing Mucus
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
EP3283004A4 (en) 2015-04-13 2018-12-05 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent
US11013403B2 (en) * 2015-09-29 2021-05-25 The Regents Of The University Of California Methods of diagnosing diseases of mucosal surfaces
US20170087100A1 (en) 2015-09-30 2017-03-30 Novaliq Gmbh Semifluorinated compounds and their compositions
EP3722274B1 (en) * 2015-09-30 2023-06-07 Novaliq GmbH 2-perfluorobutyl pentane for ophthalmic administration
DK3442480T3 (da) 2016-06-23 2020-01-13 Novaliq Gmbh Fremgangsmåde til topisk indgivelse
KR102614858B1 (ko) 2016-09-22 2023-12-18 노바리크 게엠베하 안검염 치료에 사용되는 약제학적 조성물
AU2017329983B2 (en) * 2016-09-23 2022-05-05 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
CN109803650A (zh) * 2016-09-28 2019-05-24 诺瓦利克有限责任公司 包含大麻素受体结合配体的组合物
WO2018114557A1 (en) * 2016-12-22 2018-06-28 Novaliq Gmbh Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
MX381639B (es) * 2016-12-23 2025-03-13 Novaliq Gmbh Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
WO2018129364A1 (en) 2017-01-06 2018-07-12 Palvella Therapeutics Llc Anhydrous compositions of mtor inhibitors and methods of use
PL3612228T3 (pl) 2017-04-21 2024-04-08 Dermaliq Therapeutics, Inc. Kompozycje jodu
US10717691B2 (en) 2017-05-05 2020-07-21 Novaliq Gmbh Process for the production of semifluorinated alkanes
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
JP7814839B2 (ja) 2017-09-27 2026-02-17 ノバリック ゲーエムベーハー 眼疾患の治療に使用するためのラタノプロストを含む眼科用組成物
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
US11576893B2 (en) 2018-03-02 2023-02-14 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
AU2019246035B2 (en) 2018-03-28 2024-07-18 Novaliq Gmbh Pharmaceutical composition comprising timolol
JP7855312B2 (ja) 2018-04-27 2026-05-08 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
EP3817743A4 (en) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE
EP3852734A1 (en) 2018-09-22 2021-07-28 Novaliq GmbH Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
WO2020064549A1 (en) 2018-09-27 2020-04-02 Novaliq Gmbh Lipid barrier repair
CA3112031A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
CN113518619A (zh) * 2019-01-21 2021-10-19 诺瓦利克有限责任公司 用于治疗眼部新生血管形成的药物组合物
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
WO2020239646A1 (en) 2019-05-24 2020-12-03 Novaliq Gmbh Ophthalmic composition for the treatment of ocular allergy
CN114449999A (zh) 2019-09-06 2022-05-06 诺瓦利克有限责任公司 用于治疗葡萄膜炎的眼用组合物
WO2021048803A1 (en) 2019-09-13 2021-03-18 Minas Coroneo Eye drop dispenser
EP3861857A1 (en) * 2020-02-07 2021-08-11 Novaliq GmbH Antiparasitic compositions
WO2021191273A1 (en) 2020-03-24 2021-09-30 Hovione Scientia Limited Compositions for use in treating meibomian gland dysfunction
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
EP4606396A4 (en) * 2022-11-11 2025-12-03 Cardio Navi Medtech Wuhan Co Ltd Coating solution for drug-coated balloons, coating material, drug-coated balloon, its preparation process and use
EP4665377A1 (en) * 2023-02-13 2025-12-24 Novaliq GmbH Ophthalmic composition for ocular surgery preparation in patients with ocular surface disease
AU2023270196B2 (en) * 2023-11-20 2025-06-26 Dyer, Gordon Wayne DR Method of Arthropod Egress
WO2026104414A1 (en) * 2024-11-12 2026-05-21 Dermaliq Therapeutics Gmbh Topical compositions for the treatment of alopecia areata

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
WO1989001772A1 (en) 1987-09-03 1989-03-09 University Of Georgia Research Foundation, Inc. Ocular cyclosporin composition
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
DE19536504C2 (de) * 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
DE19861012A1 (de) * 1998-03-18 1999-09-30 Pharm Pur Gmbh Behandlungsmittel für die Ophthalmologie
CZ20013769A3 (cs) * 1999-04-30 2002-03-13 Sucampo Ag Činidlo pro léčbu suchého oka
DE19938668B4 (de) * 1999-08-14 2006-01-26 Bausch & Lomb Inc. Tränenersatzmittel
US20030018044A1 (en) * 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
US20080019926A1 (en) * 2004-04-19 2008-01-24 Marie-Pierre Krafft Lung Surfactant Supplements
EP1763336A1 (en) * 2004-06-08 2007-03-21 Ocularis Pharma, Inc. Hydrophobic ophthalmic compositions and methods of use
DE102007055046A1 (de) * 2007-11-19 2009-05-28 Fluoron Gmbh Infusionslösung
PL2110126T3 (pl) 2008-04-18 2012-04-30 Novaliq Gmbh Zastosowanie do inhalacji i zakraplania semifluorowanych alkanów jako nośników substancji aktywnych w strefie wewnątrzpłucnej

Also Published As

Publication number Publication date
WO2011073134A1 (en) 2011-06-23
PT2512515E (pt) 2014-03-04
BR112012014190B8 (pt) 2021-05-25
JP6096731B2 (ja) 2017-03-15
AU2010333039B2 (en) 2014-08-28
JP6397472B2 (ja) 2018-09-26
BR112012014190B1 (pt) 2021-03-02
KR20120115977A (ko) 2012-10-19
CA2941956C (en) 2018-09-04
AU2010333039A1 (en) 2012-07-12
EP2512515B1 (en) 2013-12-25
JP2019070003A (ja) 2019-05-09
MX2012006720A (es) 2012-07-30
JP2019006803A (ja) 2019-01-17
KR101722039B1 (ko) 2017-03-31
JP6731039B2 (ja) 2020-07-29
US8614178B2 (en) 2013-12-24
BR122020020872B1 (pt) 2021-09-08
IN2012DN03128A (enExample) 2015-09-18
JP2013513586A (ja) 2013-04-22
BR122017018955B1 (pt) 2022-03-08
KR101652714B1 (ko) 2016-09-01
PL2512515T3 (pl) 2014-05-30
EP2335735A1 (en) 2011-06-22
BR112012014190A2 (pt) 2016-05-31
CA2776860A1 (en) 2011-06-23
CA2776860C (en) 2016-10-25
JP2015028064A (ja) 2015-02-12
CA2941956A1 (en) 2011-06-23
US20120244177A1 (en) 2012-09-27
JP2017078086A (ja) 2017-04-27
KR20160105533A (ko) 2016-09-06
HK1172269A1 (en) 2013-04-19
DK2512515T3 (en) 2014-03-10
ES2449308T3 (es) 2014-03-19
EP2512515A1 (en) 2012-10-24
CN102652022A (zh) 2012-08-29
CN102652022B (zh) 2014-12-17

Similar Documents

Publication Publication Date Title
JP6731039B2 (ja) ドライアイ症候群の治療のための医薬組成物
EP3518921B1 (en) Compositions comprising a cannabinoid receptor binding ligand
CN102869345B (zh) 用于治疗眼内压增高的药物组合物
JP5836473B2 (ja) 眼科用組成物
AU2017380769B2 (en) Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
HK1172269B (en) Pharmaceutical composition for treatment of dry eye syndrome
HK40036791A (en) Compositions comprising a cannabinoid receptor binding ligand

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131113

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20131113

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20131211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140407

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141001

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20141010

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141118

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141208

R150 Certificate of patent or registration of utility model

Ref document number: 5663595

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250